Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Carbone

Showing results (601-610 of 651) with videos related to

Pageof 66
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung CancersAlexander Drilon, Jessica J Lin, Thomas Filleron, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung CancerAlexander Wong, Maria Riley, Songzhu Zhao, et al.
Nature Communications|August 12, 2018
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLCRajeswara Rao Arasada, Konstantin Shilo, Tadaaki Yamada, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled AnalysisSolange Peters, Luis G Paz-Ares, Martin Reck, et al.
Cell Death Discovery|April 13, 2025
An in vivo "turning model" reveals new RanBP9 interactions in lung macrophagesYasuko Kajimura, Shuxin Dong, Anna Tessari, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 3, 2007
Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancerPinar B Yildiz, Yu Shyr, Jamshedur S M Rahman, et al.
Investigational New Drugs|December 3, 2025
Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancerDwight H Owen, Ruohan Wu, Lai Wei, et al.
Oncogene|August 5, 2018
RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patientsAnna Tessari, Kareesma Parbhoo, Meghan Pawlikowski, et al.
Clinical Lung Cancer|February 8, 2022
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not ChemoimmunotherapyYizhen Guo, Lai Wei, Sandip H Patel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomesMartin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Pageof 66

Showing results (601-610 of 651) with videos related to

Sort By:
Pageof 66
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung CancersAlexander Drilon, Jessica J Lin, Thomas Filleron, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung CancerAlexander Wong, Maria Riley, Songzhu Zhao, et al.
Nature Communications|August 12, 2018
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLCRajeswara Rao Arasada, Konstantin Shilo, Tadaaki Yamada, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled AnalysisSolange Peters, Luis G Paz-Ares, Martin Reck, et al.
Cell Death Discovery|April 13, 2025
An in vivo "turning model" reveals new RanBP9 interactions in lung macrophagesYasuko Kajimura, Shuxin Dong, Anna Tessari, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 3, 2007
Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancerPinar B Yildiz, Yu Shyr, Jamshedur S M Rahman, et al.
Investigational New Drugs|December 3, 2025
Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancerDwight H Owen, Ruohan Wu, Lai Wei, et al.
Oncogene|August 5, 2018
RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patientsAnna Tessari, Kareesma Parbhoo, Meghan Pawlikowski, et al.
Clinical Lung Cancer|February 8, 2022
Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not ChemoimmunotherapyYizhen Guo, Lai Wei, Sandip H Patel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomesMartin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Pageof 66